Domainex wins Ark discovery contract renewal
UK-based contract research services provider Domainex has extended its discovery and lead optimisation contract with drug developer Ark Therapeutics.
Domainex has worked with Ark for several years, specifically applying its medicinal chemistry, molecular biology and computer-aided drug design services to therapeutic preclinical targets nominated by Ark.
Trevor Perrior, Domainex’ research director, said that: “The synergy and teamwork between our respective scientists have been outstanding, and this collaboration has already resulted in the achievement of key breakthroughs against very challenging scientific goals.”
Earlier this week Domainex’ LeadBuilder screening technology was selected by scientists at St George’s University of London and the University of Manchester for an asthma research programme focused on the Der p1 enzyme linked to the disease.
